SOLNET-GROUP
16.1.2024 08:01:34 CET | Business Wire | Press release
Solnet Group, a leading provider of smart solar energy solutions for commerce and industry, has released a new report addressing the critical issue of safety in rooftop solar installations. Titled "Safety and Security in C&I Rooftop PV,” the white paper outlines the most important considerations rooftop solar owners and installers can take to minimize risk and protect their investments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115915852/en/
High-quality installers and components reduce risks later (Photo: Business Wire)
According to an audit by Clean Energy Associates, 97% of rooftop solar installations have major safety concerns. Solar panels that are improperly installed or maintained contribute not only to physical safety hazards such as fires but also to power outages and financial losses. A thorough understanding of these risks is necessary as more companies install rooftop solar to mitigate high energy costs and comply with new regulations. Against this backdrop, Solnet Group has compiled a review of risk-reducing technologies and best practices, focusing on how safety can impact the bottom line.
Safety in solar is highly relevant
The revised European Union’s Energy Performance of Buildings Directive will require rooftop solar on all new commercial buildings by 2026, and in renovated commercial buildings by 2027. Beyond this, up to 28% of European companies plan to voluntarily install a solar system within the next 3 years. With rapid growth in the number of solar installations, the risks grow as well. For businesses entering this market, a balance must also be found between upfront installation costs and the long-term operational costs of the array. By considering safety measures from the outset, companies can reduce both risks and costs by minimizing performance issues, keeping insurance premiums low, and mitigating disruptions.
Key findings
1. Safety is a prerequisite for investor confidence: A proactive approach to reducing risk enhances the lifespan of the array and ensures consistent energy generation. In turn, the project generates more value over its lifetime, creating assurance that rooftop solar systems are a viable investment.
2. High-quality installers and components reduce risks later: Comprehensive analyses of solar panel fires from both Germany and the UK indicate that installer error is one of the leading causes of fire incidents, illustrating the importance of a careful installation process. The right components can also mitigate fire risks and other hazards from electrical arcs. Power optimizers, which enable the panel field to be made voltage-free to facilitate firefighting and rescue operations, are increasingly required by insurers as a safety measure in solar installations.
3. Smart monitoring and maintenance tools contribute to a higher safety standard: Real-time monitoring and data analysis tools, coupled with automatic rapid shutdown, allow threats to be addressed right away. As a result, damage is minimized or even avoided, and the operator has a clearer overview of how the system is functioning. The international Zurich Insurance company has recently recommended smart solar systems in part due to the features of their panel-level power optimizers, which can be operated through remote control.
"The rationale behind Solnet’s focus on smart solar technology is not just efficiency; it's about ensuring our solar systems' quality, safety, and longevity. By incorporating features like continuous monitoring and protection mechanisms, we are elevating the safety standards of rooftop solar installations. Our report sheds light on the role of safety improvements in protecting investments and furthering the energy transition," says Arttur Kulvik, SVP Business Development at Solnet Group.
Solnet Group prioritizes safety in every stage of the design, installation, operations, and maintenance of its solar arrays. The company includes power optimizers and a suite of remote monitoring tools, including immediate fault detection alerts, as standard features in its smart solar systems.
The full report is available for download here. Solnet Group will also host a webinar on safety in commercial and industrial rooftop PV, together with representatives from SolarEdge and Zurich Insurance. Registration is open until January 18th.
The speakers at this webinar include Georg Stockschläder, RE Global Practice Leader Property at Zurich Insurance; Chris Voet, Key Accounts Director at Solar Edge; and Arttur Kulvik, SVP Business Development at Solnet Group.
About Solnet Group:
Established in 2014, Solnet Group is a rapidly growing solar energy company with units in the Netherlands, Germany, and Finland. In 2020, the company was listed as the 59th fastest-growing company in Europe on the Financial Times FT1000 list and ranked third in the energy sector. As early as 2016, Solnet Group received the Climate Solver award from WWF. Solnet Group offers comprehensive and high-quality services from consulting and planning to installation throughout Europe. To facilitate our clients' projects, we also provide services for project financing, solar plant maintenance, and repairs. Solnet Group's clientele includes major investment funds, shopping centers, retailers, as well as storage and logistics companies. For more information, visit www.solnet.group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115915852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
